Loading...

TSBX TURNSTONE BIOLOGICS CORP Expansion Plans 8-K Filing

TRNS

TSBX

TURNSTONE BIOLOGICS CORP

(TSBX)

2025 8-K

Show Summary

Show Summary

Financial Statements

Stock Delisting

Financial Results

Strategic Alternatives

Workforce Reduction

Nasdaq Compliance Notice

Financial Results

Annual Meeting Results

Financial Results Announcement

Departure of Directors

Earnings Reports

Regulation FD Disclosure

Initial Public Offerings

External Links:

Turnstone Biologics Corp. has decided to stop all clinical studies for TIDAL-01 and will explore strategic alternatives to enhance shareholder value, including potential mergers or asset sales.

AI Assistant

TURNSTONE BIOLOGICS CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.